Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 2
1992 1
1993 1
1994 3
1996 2
1997 1
1999 3
2000 3
2001 1
2002 3
2003 2
2004 2
2005 1
2006 2
2007 1
2009 3
2010 2
2011 4
2012 5
2013 4
2014 5
2015 2
2016 1
2017 6
2018 6
2019 7
2020 3
2021 4
2022 2
2023 2
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K, Sotiriou C, Bergh J, Villacampa G, Zouzos A, Hellström M, Hartman J, Foukakis T. Matikas A, et al. Among authors: engebraaten o. BMJ Open. 2025 Aug 27;15(8):e102626. doi: 10.1136/bmjopen-2025-102626. BMJ Open. 2025. PMID: 40866060 Free PMC article.
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.
Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN. Fleischer T, et al. Among authors: engebraaten o. Mol Oncol. 2024 Aug;18(8):2042-2059. doi: 10.1002/1878-0261.13656. Epub 2024 Apr 26. Mol Oncol. 2024. PMID: 38671580 Free PMC article.
The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases.
Medhus A, Schink KO, Longva AS, Engebraaten O, Berg K, Weyergang A. Medhus A, et al. Among authors: engebraaten o. Ther Adv Med Oncol. 2025 Apr 24;17:17588359251332473. doi: 10.1177/17588359251332473. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40297622 Free PMC article.
Liver X receptors induce antiproliferative effects in basal-like breast cancer.
Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O. Haugen MH, et al. Among authors: engebraaten o. Mol Oncol. 2023 Oct;17(10):2041-2055. doi: 10.1002/1878-0261.13476. Epub 2023 Jun 30. Mol Oncol. 2023. PMID: 37341140 Free PMC article.
DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC); Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN. Fleischer T, et al. Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x. Nat Commun. 2017. PMID: 29123100 Free PMC article.
Fatigue During and After Breast Cancer Therapy-A Prospective Study.
Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE. Reinertsen KV, et al. Among authors: engebraaten o. J Pain Symptom Manage. 2017 Mar;53(3):551-560. doi: 10.1016/j.jpainsymman.2016.09.011. Epub 2016 Dec 29. J Pain Symptom Manage. 2017. PMID: 28042070 Free article. Clinical Trial.
85 results